Literature DB >> 9465840

Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction.

J M van Griensven1, R W Koster, J Burggraaf, L G Huisman, C Kluft, R Kroon, R C Schoemaker, A F Cohen.   

Abstract

BACKGROUND: The removal of recombinant tissue-type plasminogen activator (rt-PA; alteplase) by the liver is so rapid that liver blood flow becomes rate determining for its clearance. In patients with myocardial infarction changes in liver blood flow may result from impaired cardiac performance or drug treatment.
OBJECTIVE: To estimate the effect of variations in liver blood flow on t-PA plasma concentrations during thrombolytic therapy.
METHODS: Fifteen patients with acute myocardial infarction were investigated in an open single-center study at the coronary care unit of University Hospital Leiden. Patients received thrombolytic treatment with 100 mg rt-PA over 3 hours. Liver blood flow was estimated by indocyanine green clearance and by Doppler echocardiography. Concentrations of t-PA antigen, t-PA activity, indocyanine green, alpha 2-antiplasmin, fibrinogen, and fibrin and fibrinogen degradation products were measured.
RESULTS: Indocyanine green clearance and clearance of both t-PA antigen (r = 0.78; p < 0:01) and t-PA activity (r = 0.54; p < 0.05) were significantly related. Significant associations between t-PA antigen and fibrin and fibrinogen degradation products and between t-PA antigen and alpha 2-antiplasmin were also found.
CONCLUSIONS: The liver blood flow of patients with myocardial infarction is inversely correlated with plasma concentrations of t-PA. In patients with severely impaired liver blood flow and heart failure, high t-PA plasma concentrations may occur if standard doses are given. This finding could contribute to optimization of the dosage of t-PA in certain patient groups.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9465840     DOI: 10.1016/S0009-9236(98)90119-9

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

Review 1.  Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction.

Authors:  Paul Tanswell; Nishit Modi; Dan Combs; Thierry Danays
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  The use of the Chandler loop to examine the interaction potential of NXY-059 on the thrombolytic properties of rtPA on human thrombi in vitro.

Authors:  N J Mutch; N R Moore; C Mattsson; H Jonasson; A R Green; N A Booth
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

3.  Comparison of pharmacokinetics of lanoteplase and alteplase during acute myocardial infarction.

Authors:  John B Kostis; Randy C Dockens; Udho Thadani; Vasnath Bethala; Carl Pepine; Wayne Leimbach; Nimish Vachharajani; Ralph H Raymond; Bruce C Stouffer; Lee K Tay; Wen Chyi Shyu; Wei-chi Liao
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Endothelial binding of recombinant tissue plasminogen activator: quantification in vivo using a recirculatory model.

Authors:  Michiel J Kemme; Rik C Schoemaker; Jacobus Burggraaf; Monique van der Linden; Marina Noordzij; Matthijs Moerland; Cornelis Kluft; Adam F Cohen
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-02       Impact factor: 2.745

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.